Theravance Biopharma, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
TBPH Nasdaq 2836 www.theravance.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Theravance Biopharma, Inc.

Wall Street Analysts Believe Theravance Bio (TBPH) Could Rally 42.15%: Here's is How to Trade - Dec 22nd, 2025 7:55 am
Why The Narrative Around Theravance Biopharma Is Shifting After Trelegy Monetization And Strategic Review - Dec 12th, 2025 7:15 am
Theravance Bio (TBPH) Down 3.7% Since Last Earnings Report: Can It Rebound? - Dec 10th, 2025 9:30 am
Theravance Biopharma (TBPH) is a Great Momentum Stock: Should You Buy? - Dec 8th, 2025 10:00 am
Does Theravance Bio (TBPH) Have the Potential to Rally 30.64% as Wall Street Analysts Expect? - Dec 5th, 2025 7:55 am
Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025 - Nov 20th, 2025 9:00 am
Theravance Biopharma to Participate in Upcoming Investor Conferences - Nov 19th, 2025 4:00 am
How Recent Shifts Are Reshaping the Story Behind Theravance Biopharma’s Investment Appeal - Nov 12th, 2025 4:10 am
Here's Why Shares in Theravance Biopharma Exploded Today - Nov 11th, 2025 12:14 pm
Theravance's Q3 Earnings Surpass Estimates, Revenues Match - Nov 11th, 2025 8:10 am
Theravance Biopharma Inc (TBPH) Q3 2025 Earnings Call Highlights: Record Sales and Strategic ... - Nov 10th, 2025 10:04 pm
Theravance Biopharma (TBPH) Q3 Earnings and Revenues Beat Estimates - Nov 10th, 2025 3:20 pm
Theravance Bio: Q3 Earnings Snapshot - Nov 10th, 2025 2:20 pm
Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Nov 10th, 2025 2:05 pm
VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates - Nov 6th, 2025 7:15 am
Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System - Oct 29th, 2025 4:00 am
Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025 - Oct 27th, 2025 4:00 am
Theravance Biopharma Launches Disease Education Campaign to Advance Scientific Understanding of Neurogenic Orthostatic Hypotension Due to Multiple System Atrophy - Oct 16th, 2025 6:05 am
Theravance Biopharma to Present New Analyses Highlighting YUPELRI® (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting - Oct 14th, 2025 4:00 am
How Recent Developments Are Changing the Theravance Biopharma Investment Story - Sep 21st, 2025 5:01 am